Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Announces Earnings Results

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) issued its quarterly earnings results on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23), FiscalAI reports.

Damora Therapeutics, Inc. Common Stock Stock Up 4.6%

Shares of Damora Therapeutics, Inc. Common Stock stock opened at $24.16 on Thursday. Damora Therapeutics, Inc. Common Stock has a twelve month low of $2.45 and a twelve month high of $38.33. The business has a 50-day moving average price of $25.77 and a 200-day moving average price of $23.94. The firm has a market cap of $1.46 billion, a price-to-earnings ratio of -2.00 and a beta of 1.50.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DMRA. Ikarian Capital LLC purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth approximately $6,574,000. Jain Global LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $2,774,000. Remedium Capital Partners LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at $2,772,000. Boothbay Fund Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $2,204,000. Finally, Geode Capital Management LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the fourth quarter worth $266,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on DMRA. Guggenheim restated a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. Evercore began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective for the company. Lifesci Capital upgraded Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd. Royal Bank Of Canada began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective for the company. Finally, UBS Group began coverage on Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, February 17th. They set a “buy” rating and a $45.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $43.40.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.